Target Name: GPN3
NCBI ID: G51184
Review Report on GPN3 Target / Biomarker Content of Review Report on GPN3 Target / Biomarker
GPN3
Other Name(s): ATP-binding domain 1 family member C | ATP binding domain 1 family, member C | protein x 0004 | ATPBD1C | GPN-loop GTPase 3 (isoform 1) | GPN-loop GTPase 3, transcript variant 1 | Protein x 0004 | GPN-loop GTPase 3 | GPN3_HUMAN | GPN3 variant 1

GPN3: A Protein Implicated in Disease and Therapeutic Applications

GPN3 (ATP-binding domain 1 family member C) is a protein that is expressed in various tissues and organs throughout the body. It is a member of the GPN3 family, which is known for its role in various cellular processes, including cell signaling, DNA replication, and protein synthesis. GPN3 is highly conserved across various species, and it has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

GPN3 is a protein that is composed of several domains, including an ATP-binding domain, a catalytic domain, and a cytoplasmic domain. The ATP-binding domain is the most well-studied, and it is known for its role in regulating various cellular processes, including cell signaling, DNA replication, and protein synthesis. The catalytic domain is known for its role in catalyzing various chemical reactions, including the transfer of a phosphate group to other molecules. The cytoplasmic domain is responsible for the protein's localization and stability in the cytoplasm.

GPN3 has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GPN3 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have also shown that GPN3 is involved in the development of cancer, and that it can serve as a potential drug target or biomarker for cancer.

In addition to its potential role in disease, GPN3 has also been shown to have several potential therapeutic applications. For example, GPN3 has been shown to be a potent inhibitor of the protein kinase A尾2, which is involved in the development of Alzheimer's disease. Studies have also shown that GPN3 can be used to treat various cancers, including breast, ovarian, and colorectal cancers. In addition, GPN3 has been shown to have anti-inflammatory effects, which may have potential therapeutic applications in the treatment of autoimmune disorders.

GPN3 is a protein that has been studied extensively, and there is a growing body of research that is focused on understanding its role in various cellular processes. While more research is needed, the studies that have been done suggest that GPN3 is a protein that is worth further investigation as a potential drug target or biomarker.

Protein Name: GPN-loop GTPase 3

Functions: Small GTPase required for proper localization of RNA polymerase II (RNAPII). May act at an RNAP assembly step prior to nuclear import

The "GPN3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPN3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2